Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Announces Sale of its Direct Equity Investment in Moderna

12/02/2020 | 07:13am EST

December 2, 2020 7:00 am EST

KENILWORTH, N.J., Dec. 2, 2020 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, divested its direct holding in Moderna (MRNA) in the first half of the fourth quarter. As such, Merck expects to record a small fourth-quarter gain, which will be reflected in 'Other (income) expense, net' (OIE).

Merck's direct investment in MRNA was initiated in 2015 and increased in 2018, reflecting a research collaboration between the two companies that was announced and expanded in those years. Merck achieved a substantial gain on its direct holding in MRNA over the life of the investment, particularly in 2020 given the substantial appreciation in MRNA's stock price. Merck retains exposure to MRNA indirectly through its investment in venture funds. As a reminder, gains/losses from such holdings are recorded on a one-quarter lag (e.g. the current quarter change in value of holdings in venture funds are reflected in the subsequent quarter's OIE).

Merck and Moderna continue to collaborate on the development of personalized cancer vaccines as well as a cancer vaccine that encodes the four most common KRAS mutations.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2019 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Media:
Pamela Eisele
(267) 305-3558

Investor Contacts:
Peter Dannenbaum
(908) 740-1037

Disclaimer

Merck & Co. Inc. published this content on 02 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 December 2020 12:12:04 UTC


© Publicnow 2020
All news about MERCK & CO., INC.
06:38aMERCK : Announces U.S. FDA Approval of VERQUVO
AQ
06:38aMERCK : Bayer - U.S. FDA approves vericiguat for patients with symptomatic chron..
AQ
01/20MERCK : Canada and MaRS Team Up to Launch Lung Cancer Innovation Challenge
AQ
01/20MERCK : Gets FDA Approval for Verquvo
DJ
01/20MERCK : Receives US FDA Approval of Heart Failure Treatment Verquvo
MT
01/20MERCK : Announces U.S. FDA Approval of VERQUVO® (vericiguat)
BU
01/20UPDATE : DeepMatter Jumps 18% on Multi-Year Data Licensing Contract with Merck's..
MT
01/20DeepMatter Lands Multi-Year Data Licensing Contract With Merck's Life Science..
MT
01/14Philips Partners with Merck to Develop Digital Systems for Fertility Treatmen..
MT
01/13Ligand Pharmaceuticals to Receive $1.5 Million Milestone Payment From Merck
MT
More news
Financials (USD)
Sales 2020 48 200 M - -
Net income 2020 12 145 M - -
Net Debt 2020 15 159 M - -
P/E ratio 2020 17,1x
Yield 2020 3,02%
Capitalization 205 B 205 B -
EV / Sales 2020 4,58x
EV / Sales 2021 4,21x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 96,95 $
Last Close Price 81,18 $
Spread / Highest target 31,8%
Spread / Average Target 19,4%
Spread / Lowest Target 4,71%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.0.81%208 627
JOHNSON & JOHNSON3.18%427 472
ROCHE HOLDING AG3.56%308 129
NOVARTIS AG2.82%219 666
PFIZER INC.-0.84%202 881
ABBVIE INC.5.11%198 828